Acromegaly: Patient And Physician Perspectives

Tulane University

Status

Completed

Conditions

Acromegaly

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT03613623

2018-879

Details and patient eligibility

About

The purpose of the study is to assess the experiences of individuals with acromegaly who are receiving injections as part of their treatment regimen. Another objective of the study is to compare the patients' perception with their doctors' perceptions. The answers are important to help researchers and physicians understand what it is really like to take currently available treatments so that they can make efforts to improve patients' healthcare experiences, reduce treatment burden and, ultimately, improve patient's quality of life.

Enrollment

152 patients

Sex

All

Ages

18 to 94 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age >=18 years-old and <95 years-old
Patient self-reported acromegaly diagnosis which will be further confirmed by a knowledge screening based on current medications and doses
Currently on injectable Somatostatin analogues (SSA), Sandostatin® LAR or Somatuline® Depot, for >=12 months
Have not had a change in dosage of their acromegaly treatment at the time of or since their last office visit
Have seen their treating acromegaly physician within the past 12 +/-2 months NOTE: This timeframe allows two additional months for scheduling an appointment with their physician, since most patients should see their acromegaly physician at least once every 12 months
Ability to read and understand English
Live and receive acromegaly treatments in the US
Willing to provide signed informed consent

Exclusion criteria